CASI News and Press, CASI Pharmaceuticals Inc. From 05/26/22

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT PR Newswire ROCKVILLE, Md. and BEIJING , May 26, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative t...

Casi Pharmaceuticals (NASDAQ:CASI) is granting Beijing Tianshi Tongda Pharmaceuticals Technology an exclusive, perpetual, worldwide license for CID-103 for autoimmune diseases. Under the sublicense agreement, Casi will maintain the exclusive commercialization and co-marketing rights...

CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD PR Newswire ~ CASI to receive upfront payment of $10 million in two instalments ~ ~ CASI through its whol...

The following slide deck was published by CASI Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: CASI Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

CASI Pharmaceuticals, Inc. (CASI) Q1 2022 Earnings Conference Call May 12, 2022, 08:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Larry Zhang - President Alexander Zukiwski - Executive Vice President and Chief Medical Officer James Goldsc...

CASI Pharmaceuticals press release (NASDAQ:CASI): Q1 GAAP EPS of -$0.06 beats by $0.03. Revenue of $9.06M (+57.8% Y/Y) misses by $0.18M. For further details see: CASI Pharmaceuticals GAAP EPS of -$0.06 beats by $0.03, revenue of $9.06M misses by $0.18M

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS PR Newswire ROCKVILLE, Md. and BEIJING , May 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commer...

CASI Pharmaceuticals (NASDAQ:CASI) Q1 consensus EPS estimate is -$0.06 and consensus revenue estimate is $9.24M (+61.0% Y/Y). CASI is scheduled to announce Q1 earnings results on Thursday, May 12, before market open. For further details see: CASI Pharmaceuticals Q1 2022 E...

AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,OTCQX:QTRHF,RDCM,OTCPK:RWEOY,SCYX,SFL...

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 PR Newswire ROCKVILLE, Md. and BEIJING , May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused ...